Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
McKinsey
Deloitte
Healthtrust
Johnson and Johnson
UBS
Fish and Richardson
Cerilliant
AstraZeneca

Generated: January 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GALLIUM CITRATE GA 67

« Back to Dashboard

Clinical Trials for Gallium Citrate Ga 67

Trial ID Title Status Sponsor Phase Summary
NCT00477503 Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA Terminated M.D. Anderson Cancer Center Phase 1 - Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging. - Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during remission of leptomeningeal metastasis (LM) and during LM occurrence, remission and recurrence.
NCT03116945 Novel Gallium Imaging in Hepatocellular Carcinoma Recruiting Radiological Society of North America Phase 2 The aim of the present study is to validate the uptake of novel, positron emitting radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging modality for identification of HCC lesions in the liver. The investigators intend to use the results of this preliminary study to fuel further studies in the utility of 68Ga-citrate PET/CT for HCC treatment monitoring.
NCT03116945 Novel Gallium Imaging in Hepatocellular Carcinoma Recruiting Rutgers, The State University of New Jersey Phase 2 The aim of the present study is to validate the uptake of novel, positron emitting radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging modality for identification of HCC lesions in the liver. The investigators intend to use the results of this preliminary study to fuel further studies in the utility of 68Ga-citrate PET/CT for HCC treatment monitoring.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Gallium Citrate Ga 67

Condition Name

Condition Name for Gallium Citrate Ga 67
Intervention Trials
Joint Prosthesis 1
Hepatocellular Carcinoma 1
Central Nervous System Tumors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gallium Citrate Ga 67
Intervention Trials
Carcinoma 1
Nervous System Neoplasms 1
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gallium Citrate Ga 67

Trials by Country

Trials by Country for Gallium Citrate Ga 67
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gallium Citrate Ga 67
Location Trials
New Jersey 2
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gallium Citrate Ga 67

Clinical Trial Phase

Clinical Trial Phase for Gallium Citrate Ga 67
Clinical Trial Phase Trials
Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gallium Citrate Ga 67
Clinical Trial Phase Trials
Recruiting 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gallium Citrate Ga 67

Sponsor Name

Sponsor Name for Gallium Citrate Ga 67
Sponsor Trials
Rutgers, The State University of New Jersey 2
Radiological Society of North America 1
M.D. Anderson Cancer Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gallium Citrate Ga 67
Sponsor Trials
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
UBS
Chubb
Colorcon
Chinese Patent Office
Merck
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.